Shaya Mokfi
Internal Medicine · Mishawaka, INNPI 1912952151
Payments from drug & device makers
Across 62 payments — averaging $26.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$271
- Sunovion Pharmaceuticals Inc.$216
- Novartis$145
- Bayer$144
- Teva Pharmaceuticals USA, Inc.$141
- Johnson & Johnson$138
- plus $615 from 15 others
What the payments were for
- Food & beverage$1,55993%
- Education$1117%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 3 | $271 |
| Sunovion Pharmaceuticals Inc. | 17 | $216 |
| Novartis | 8 | $145 |
| Bayer | 2 | $144 |
| Teva Pharmaceuticals USA, Inc. | 3 | $141 |
| Johnson & Johnson | 8 | $138 |
| Lilly USA, LLC | 1 | $125 |
| AbbVie(2 entities) | 6 | $103 |
| Globus Medical | 1 | $92 |
| Kowa Pharmaceuticals America, Inc. | 1 | $77 |
| AstraZeneca | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Biogen | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Medtronic | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,671 in reported general payments places this provider in the 80th percentile of 1,747 internal medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 442 | $169,830 |
| IngrezzaValbenazine Tosylate | 32 | $157,309 |
| JardianceEmpagliflozin | 195 | $65,106 |
| XareltoRivaroxaban | 106 | $45,834 |
| TrulicityDulaglutide | 38 | $35,705 |
| EntrestoSacubitril/Valsartan | 69 | $25,310 |
| XifaxanRifaximin | 15 | $23,125 |
| JanuviaSitagliptin Phosphate | 29 | $19,308 |
| OzempicSemaglutide | 17 | $17,378 |
| Paliperidone ErPaliperidone | 28 | $15,002 |
| MounjaroTirzepatide | 19 | $14,484 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 43 | $13,451 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $11,142 |
| MyrbetriqMirabegron | 40 | $10,708 |
| MultaqDronedarone Hcl | 24 | $9,807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $271 | $157,30932 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Olanzapine | $125 | $57,039180 claims |
| Johnson & JohnsonXarelto | $138 | $45,834106 claims |
| NovartisEntresto | $145 | $25,31069 claims |
| Novo NordiskOzempic | $16 | $17,37817 claims |
| AstraZenecaFarxiga | $35 | $8,19828 claims |
| AbbVieSynthroid | $103 | $7,20165 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $21 | $5,76115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Mishawaka
- Alexander GatzimosMishawaka$30K
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.